The atherogenic risk of antihypertensive therapy.
The past 20 years have demonstrated the unqualified success of antihypertensive therapy in reducing morbidity and mortality from cardiovascular and cerebrovascular disease. Evidence mounts, however, that certain antihypertensive agents may, themselves, have an adverse effect on the development and progression of cardiovascular disease. The dramatic reductions in the incidence of cerebrovascular events and congestive heart failure among patients receiving antihypertensive therapy have not been paralleled by similar reductions in cardiac morbidity or mortality. Several lines of evidence now point to the possibility that adverse metabolic changes are induced by certain antihypertensive drugs. These changes may offset, negate, or even reverse the potential benefit afforded by successful blood pressure control.